Efficient engineering of chimeric antigen receptors (CARs), TCRs, and directed antibodies with enhanced affinity and specificity requires detailed characterization of neoepitope/MHC-I complexes, together with receptor sequences (i.e. from TCR repertoire analysis80) and evaluation of cytotoxic tumor killing18,23. This evidence concerns the gene CARS1 and neoplasm.